|
|
|
| Application Value of TBA/HDL-C and cys C in Short-Term Prognosis Evaluation of Patients with ACLF |
| WANG Huiqing, LI Hui, LIU Beibei |
| Department of Gastroenterology, Zhumadian First People's Hospital, Zhumadian Henan 463000 |
|
|
|
|
Abstract 【Objective】To explore the application value of the ratio of total bile acid (TBA) to high-density lipoprotein cholesterol (HDL-C) (TBA/HDL-C) combined with cystatin C (cys C) in evaluating the short-term prognosis of patients with acute-on-chronic liver failure (ACLF). 【Methods】The clinical data of 87 ACLF patients admitted to our hospital from January 2021 to October 2023 were retrospectively analyzed. According to the survival status, the patients were divided into the survival group (n=38) and the death group (n=49). General information of the patients was collected, and the levels of TBA, HDL-C and cys C at admission were recorded, with TBA/HDL-C calculated. Receiver operating characteristic (ROC) curve was used to analyze the efficacy of TBA/HDL-C and cys C in predicting the short-term prognosis of ACLF patients. Kappa consistency test was used to analyze the consistency between the prediction of short-term prognosis by TBA/HDL-C, cys C and the actual prognosis. 【Results】The serum levels of HDL-C and TBA in the survival group were higher than those in the death group, while the levels of TBA/HDL-C and cys C were lower than those in the death group, with statistically significant differences (P<0.05). The Kappa values of TBA/HDL-C, cys C, and their combination in predicting short-term prognosis compared with actual prognosis were 0.609, 0.626, and 0.716, respectively. The combination showed a higher degree of consistency with the actual prognosis. TBA/HDL-C and cys C had high sensitivity, specificity, accuracy, positive predictive value, and negative predictive value in predicting the short-term prognosis of ACLF, and their combination showed better predictive performance, especially in sensitivity and negative predictive value. ROC curve analysis showed that both TBA/HDL-C and cys C alone had good predictive efficacy, and the area under the curve (AUC) of their combination was 0.854, which was superior to either of them alone (P<0.05).【Conclusion】The combination of TBA/HDL-C and cys C can effectively predict the short-term prognosis of ACLF patients, and has important reference value for clinical treatment and prognosis evaluation of patients.
|
|
Received: 12 June 2024
|
|
|
|
|
|
[1] 黄振华,何关,许丽霞,等.NLR联合MLR对乙型肝炎病毒相关慢加急性肝衰竭患者人工肝治疗短期预后的预测价值[J].中国现代医学杂志,2020,30(17):13-19.
[2] 于璐.系统护理干预血浆置换联合双重血浆分子吸附系统治疗慢加急性肝衰竭患者的疗效观察[J].海军医学杂志,2019,40(6):584-588.
[3] 雷金艳,郭丽颖,朱波,等.复方茵陈加减方对慢加急性肝衰竭患者的临床疗效[J].中西医结合肝病杂志,2023,33(2):122-125.
[4] 李绍军.格拉斯哥预后评分(GPS)对HBV相关慢加急性肝衰竭患者死亡的预测价值[D].乌鲁木齐:新疆医科大学,2015.
[5] 胡辉,黄贝贝,宁玲,等.HBV相关慢加急性肝衰竭患者短期预后预测模型的建立与评价[J].临床肝胆病杂志,2020,36(1):123-127.
[6] 徐曼曼,余朋飞,陈煜,等.美国胃肠病学会《慢加急性肝衰竭临床指南》摘译[J].中华肝脏病杂志,2022,30(2):199-203.
[7] 杨颜榕,徐曼曼,陈煜.肝硬化慢加急性肝衰竭的发病诱因及管理[J].解放军医学杂志,2023,48(1):7-12.
[8] 向艳萍,李自琼,赵栩,等.经人工肝支持系统治疗的慢加急性肝衰竭患者短期预后的危险因素分析[J].检验医学与临床,2024,21(10):1492-1496.
[9] 周学士,苏婷婷,杜合娟,等.人工肝多模式序贯联合治疗乙型肝炎病毒相关慢加急性肝衰竭患者的近期疗效观察[J].中华传染病杂志,2022,40(12):722-728.
[10] 徐曼曼,武羽,李珊珊,等.不同预后评分在慢加急性肝衰竭肝移植决策中的应用[J].中华肝脏病杂志,2023,31(6):574-581.
[11] 武超玉,唐公恩,王万鹏,等.血清NGAL和cys C用于ACLF相关AKI的诊断价值研究[J].河北医药,2018,40(21):3218-3222.
[12] 王娟,章颖,刘先进,等.凝血酶原国际标准化比值/白蛋白、终末期肝病模型联合血清钠和高密度脂蛋白胆固醇联合检测对慢加急性肝衰竭患者预后的预测价值[J].实用临床医药杂志,2023,27(19):94-100.
[13] 孙天乙,黄圣楷,孙龙.总胆汁酸/血小板对 HBV 相关肝纤维化的诊断价值评估[J].海南医学院学报,2023,29(20):1574-1577.
[14] 万志红,王建军,谢国明,等.血清胱抑素C对慢加急性肝衰竭患者肾损伤的早期诊断意义[J].临床肝胆病杂志,2014(7):666-669.
[15] LI F F, MIAO L Y, SUN H,et al. Establishment of a new acute-on-chronic liver failure model[J].Acta Pharmaceutica Sinica B,2017,7(3):326-333. |
|
|
|
2025, Vol. 42 
